# US 2014/0155341 A1 · Use of ss'-dimethyl-gliotoxin as diagnostic marker of pathologies caused by gliotoxin-producing fungi or their derivatives > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0155341 A1 - Document ID: US20140155341A1 - Status: Published application - Kind: A1 - Application number: 14/114,744 - Filed: 2012-05-04 - Published: 2014-06-05 - Earliest claimed: 2011-05-04 - Inventors: Julian Pardo Jimeno; Eva M. Galvez Buerba; M. Pilar Domingo Regidor - Web page: https://patentgrep.com/patent/US20140155341A1 ## CPC - C12Q 1/04: Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor {(C12Q1/6897 takes precedence)} - A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} - G01N 33/56961: {Plant cells or fungi} - G01N 2333/38: from Aspergillus - G01N 2333/385: from Penicillium - Y10T 436/147777: Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.] - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION ## Abstract The present invention relates to an in vitro method of diagnosis, prognosis and/or monitoring of pathologies caused by gliotoxin-producing fungi or their derivatives, characterized in that it is based on the detection of SS′-dimethyl-gliotoxin in a biological sample. Also relates to the use of the SS′-dimethyl-gliotoxin as marker for the diagnosis, prognosis and/or monitoring of pathologies caused by gliotoxin-producing fungi or their derivatives in a subject. ## Claims ### Claim 1 A method for the in vitro diagnosis, prognosis and/or monitoring of pathologies caused by gliotoxin-producing fungi or their derivatives characterized by the detection of SS′-dimethyl-gliotoxin in the biological sample of a subject. ### Claim 2 (depends on 1) The method according to claim 1, wherein the detection is carried out using the following steps: a) separation of SS′-dimethyl-gliotoxin in the sample by chromatography; b) detection and/or quantification of the compound separated in (a) by ultraviolet spectroscopy. ### Claim 3 (depends on 2) The method according to claim 2, wherein the separation of step (a) is carried out by thin layer chromatography (HPTLC). ### Claim 4 (depends on 3) The method according to claim 3, wherein the detection of step (b) is performed between 220 and 400 nm. ### Claim 5 (depends on 4) The method according to claim 4, wherein the detection of step (b) is performed at 280 nm. ### Claim 6 (depends on 1) The method according to claim 1, wherein the fungus is a mould or a yeast. ### Claim 7 (canceled) ### Claim 8 (depends on 6) The method according to claim 6 wherein the fungus is a mould of the genus Aspergillus or Penicillium. ### Claim 9 (canceled) ### Claim 10 (depends on 8) The method according to claim 8 wherein the mould is Aspergillus fumigatus. ### Claim 11 (depends on 1) The method according to claim 1, wherein the pathology is aspergilliosis. ### Claim 12 (depends on 1) The method according to claim 1, wherein the pathology is penicilliosis. ### Claim 13 (depends on 1) The method according to claim 1, wherein the subject is human. ### Claim 14 (depends on 1) The method according to claim 1, wherein the subject is an immunodepressed subject. ### Claim 15 (depends on 1) The method according to claim 1, wherein the biological sample is selected from serum, plasma, blood or bronchoalveolar lavage. ### Claim 16 (depends on 1) The method according to claim 1, wherein it further comprises the detection of biological components or metabolites of fungi, wherein said components or metabolites are selected from the list comprising: galactomannan, (1-3)beta-D-glucan, DNA, antigens, gliotoxin, gliotoxin E, Gliotoxin G, S-methylgliotoxin, helvolic acid, sirodesmins, aranotin, emestryn, dithiosilvatin, sporidesmin, sterigmatocystin, aflatoxins, ochratoxins, fumonisins or any of their combinations. ### Claim 17 (depends on 16) The method according to claim 16, wherein the detection is of gliotoxin. ### Claim 18 (depends on 17) The method according to claim 17, wherein gliotoxin is detected by the following steps: a) separation of gliotoxin in the sample, by chromatography; b) detection and/or quantification of the compound separated in (a) by ultraviolet spectroscopy. ### Claim 19 (depends on 18) The method according to claim 18, wherein the detection of step (b), for the gliotoxin, is performed between 220-400 nm. ### Claim 20 (depends on 9) The method according to claim 9, wherein the detection of step (b), for the gliotoxin, is performed at 280 and 367 nm. ### Claim at position 21 21-30. (canceled) ### Claim 31 (depends on 11) The method according to claim 11, wherein the aspergillosis is invasive aspergillosis. ### Claim 32 (depends on 1) The method according to claim 1, wherein the SS′-dimethyl-gliotoxin is detected, the subject is administered an antifungal treatment.